Compare Incyte Corporation (INCY) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Peloton Interactive Inc — how do they compare? Incyte Corporation trades at $118.05 (market cap $23.11B), while Peloton Interactive Inc trades at $6.46 (market cap $2.82B). The key difference: Incyte Corporation is far larger — about 8.2× Peloton Interactive Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals.
| INCY | PTON | |
|---|---|---|
Market Cap | $23.11B | $2.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $9.00 |
52-Week Low | $67.38 | $3.71 |
Enterprise Value | $19.13B | $3.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Peloton (PTON) trades at $6.545, up 6.94% today, showing stabilization after years of decline. The company achieved positive operating cash flow of $333M in 2025 and is projected to return to net profitability in 2026. Technical indicators are bullish on moving averages, while fundamentals reveal high debt levels but improving margins. Recent news highlights leadership changes and inclusion in the S&P SmallCap 600 index as potential catalysts.
Outlook remains cautious but improving; PTON offers turnaround potential with cost controls driving cash flow, but risks include persistent revenue declines and substantial long-term debt of $1.49B. Analyst consensus is mixed with a $7.50 price target, suggesting modest upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
